Kalvista Pharmaceuticals Inc (OQ:KALV)

Business Focus: Biopharmaceuticals

Jul 15, 2019 07:30 am ET
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided an operational update and released financial results for the fiscal year ended April 30, 2019.
Jul 01, 2019 07:35 am ET
 KalVista Pharmaceuticals Announces Changes to Board of Directors
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Martin Edwards has been appointed and Richard H. Aldrich is resigning from the Company’s Board of Directors. Both changes are part of a planned transition and are effective immediately.
Jun 04, 2019 07:30 am ET
KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors announced data was presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal.
May 30, 2019 07:30 am ET
KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Jefferies Healthcare Conference on Thursday, June 6, 2019, at 4:00 p.m. ET in New York, NY.
May 28, 2019 07:30 am ET
KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced data that was presented at the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary.
May 20, 2019 07:30 am ET
KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that data has been accepted for presentation at both the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary and European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal.
Apr 30, 2019 07:30 am ET
KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced data from a poster presentation on Monday, April 29, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019 in Vancouver, Canada.
Apr 22, 2019 07:30 am ET
KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr. Soland most recently served as the Chief Executive Officer of uniQure N.V. and Senior Vice President and Chief Operating Officer of ViroPharma.
Apr 03, 2019 07:30 am ET
KalVista Pharmaceuticals to Present at Needham Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, at 2:10 p.m. ET in New York, NY.
Apr 01, 2019 07:40 am ET
Recent Analysis Shows Wells Fargo, Public Service Enterprise Group, Apartment Investment and Management, Gentherm, Connecticut Water Service, and KalVista Pharmaceuticals Market Influences — Renewed O
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Wells Fargo & Company (NYSE:WFC), Public Service Enterprise Group...
Mar 27, 2019 07:30 am ET
KalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business Officer
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the promotion of Ben Palleiko to Chief Business Officer in addition to his current role as Chief Financial Officer, effective immediately.
Mar 14, 2019 07:30 am ET
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal third quarter ended January 31, 2019.
Feb 25, 2019 07:30 am ET
KalVista Pharmaceuticals Presents Data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced data from a poster presentation given Saturday, February 23, at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 in San Francisco, CA.
Feb 01, 2019 07:30 am ET
KalVista Pharmaceuticals Appoints Brian J. G. Pereira, MD to Board of Directors
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Brian Pereira has been appointed to its Board of Directors effective February 1, 2019. Dr. Pereira is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies. He has been President & CEO of Visterra Inc. since 2013 and previously served as President & CEO of AMAG Pharmaceuticals.
Jan 25, 2019 07:50 am ET
Research Report Identifies TechnipFMC plc, Glu Mobile, EPR Properties, Apartment Investment and Management, KalVista Pharmaceuticals, and DXP Enterprises with Renewed Outlook — Fundamental Analysis, C
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TechnipFMC plc (NYSE:FTI), Glu Mobile Inc. (NASDAQ:GLUU), EPR...
Jan 04, 2019 07:30 am ET
KalVista Pharmaceuticals Provides Development Update and 2019 Clinical Plans
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided a development update on its oral plasma kallikrein inhibitor portfolio.
Dec 14, 2018 07:30 am ET
KalVista Pharmaceuticals Reports Fiscal Second Quarter Results
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal second quarter ended October 31, 2018.
Nov 12, 2018 07:30 am ET
KalVista Pharmaceuticals Provides Clinical Update on KVD900
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on the hereditary angioedema (HAE) candidate KVD900.
Nov 06, 2018 07:30 am ET
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the following upcoming investor conferences:
Oct 18, 2018 08:35 am ET
Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive Networks, KalVista Pharmaceuticals, and Adtalem Global Education — New Horizons, Emerging T
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), Arconic Inc. (NYSE:ARNC),...
Sep 25, 2018 07:30 am ET
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 8:00 a.m. ET in New York, NY.
Sep 14, 2018 07:30 am ET
KalVista Pharmaceuticals Reports Fiscal First Quarter Results
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal first quarter ended July 31, 2018.
Sep 10, 2018 04:01 pm ET
KalVista Pharmaceuticals Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Over-allotment Option to Purchase Additional Shares
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the closing of its previously announced underwritten public offering of 4,600,000 shares, which included the exercise in full by the underwriters of their over-allotment option to purchase 600,000 additional shares of common stock, at a price to the public of $17.00 per share. After giving effect to the full exercise of the over-allotment o
Sep 06, 2018 09:15 am ET
KalVista Pharmaceuticals Announces Pricing of Public Offering of Common Stock
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be approximately $68.0 million. In addition,
Sep 05, 2018 04:02 pm ET
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, announced today that it intends to offer shares of its common stock in an underwritten public offering. In addition, KalVista intends to grant the underwriters a 30-day over-allotment option to purchase additional shares of its common stock offered in the public offering at the public offering price less underwriting discounts and commissions. All of the shares w
Aug 27, 2018 07:45 am ET
Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), IZEA Inc. (NASDAQ:IZEA),...
Aug 07, 2018 07:30 am ET
KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018, at 3:40 p.m. ET in New York, NY.
Jul 31, 2018 07:00 am ET
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal fourth quarter and full year ended April 30, 2018. KalVista also announced the sale of approximately $14.6 million in common stock to Venrock Healthcare Capital Partners (Venrock) and BVF Partners L.P. (BVF) in a registered direct transaction.
Jun 25, 2018 07:35 am ET
Recent Analysis Shows Cigna, Basic Energy Services, KalVista Pharmaceuticals, QuinStreet, Armstrong World Industries, and NMI Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cigna Corporation (NYSE:CI), Basic Energy Services, Inc. (NYSE:BAS),...
May 31, 2018 07:30 am ET
KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 8, 2018, at 9:30 a.m. ET in New York, NY.
May 29, 2018 07:30 am ET
KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data from a poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich, Germany.
May 16, 2018 07:30 am ET
KalVista Pharmaceuticals Recognizes HAE Day
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced recognition of patient organizations from around the world holding a global awareness day for the condition hereditary angioedema (HAE). In support of this annual awareness day, KalVista is sponsoring and attending the HAE Global Conference to be held in Vienna, Austria on May 17-20th, 2018.
May 07, 2018 07:30 am ET
Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals — What Drives Gro
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Energy Transfer Partners, L.P....
May 02, 2018 07:30 am ET
KalVista Pharmaceuticals Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data in support of the Company’s development activities in diabetic macular edema (DME) from an oral presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting in Honolulu, Hawaii.
Apr 18, 2018 07:30 am ET
KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that data in support of KalVista’s ongoing development in diabetic macular edema (DME) has been accepted for oral presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting on May 1, 2018 in Honolulu, Hawaii.
Mar 16, 2018 07:30 am ET
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today reported operational and financial results for the fiscal third quarter ended January 31, 2018.
Mar 05, 2018 07:50 am ET
New Research Coverage Highlights KalVista Pharmaceuticals, Forestar Group, Unum Group, 22nd Century Group, Chevron, and The Michaels Companies — Consolidated Revenues, Company Growth, and Expectations
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), Forestar Group...
Mar 05, 2018 07:30 am ET
KalVista Pharmaceuticals to Present at 30th Annual ROTH Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the ROTH Conference on Monday, March 12, 2018, at 2:30 p.m. PT in Orange County, CA.
Jan 05, 2018 07:30 am ET
KalVista Pharmaceuticals Commences Two Clinical Trials
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the initiation of two clinical trials: a Phase 2 proof-of-concept clinical trial evaluating the safety, tolerability, and efficacy of KVD001 as a treatment for diabetic macular edema (DME), as well as a Phase 1 trial for KVD 900, the second candidate in the oral hereditary angioedema (HAE) portfolio. Both trials commenced in December 2017, in
Dec 14, 2017 07:30 am ET
KalVista Pharmaceuticals Reports Fiscal Second Quarter Results
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today reported operational and financial results for the fiscal second quarter ended October 31, 2017.
Nov 08, 2017 07:30 am ET
KalVista Pharmaceuticals to Present at Stifel Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 15, 2017, at 8:00 a.m. EST in New York City.
Nov 01, 2017 08:00 am ET
Investor Expectations to Drive Momentum within VWR, The Michaels Companies, KalVista Pharmaceuticals, PACCAR, Jaguar Health, and CPI Card Group – Discovering Underlying Factors of Influence
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of VWR Corporation (NASDAQ:VWR), The Michaels Companies,...
Oct 10, 2017 07:30 am ET
KalVista Pharmaceuticals Announces Collaboration with Merck
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for KVD001, the Company’s investigational intravitreal (IVT) injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon
Aug 08, 2017 07:30 am ET
KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Aug. 08, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017, at 3:05 p.m. EDT in New York City....
Mar 16, 2017 04:15 pm ET
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
–  Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for HAE –– Intravitreal DME Program Remains on Track for Phase 2 in 2017 –– Company Expects to be Well-Funded Through Data Inflection Points –...
Mar 09, 2017 07:30 am ET
KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, March 09, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the appointment of Andreas Maetzel, M.D., M.Sc., Ph.D, to the role of Senior Vice President, Medical....
Jan 20, 2017 11:01 pm ET
Johnson & Weaver, LLP Initiates Investigations of Rent-A-Center, Inc., KalVista Pharmaceuticals, Inc., NovoCure Limited and Inotek Pharmaceuticals Corp.
SAN DIEGO, Jan. 20, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Rent-A-Center, Inc., KalVista Pharmaceuticals, Inc., NovoCure Limited, and Inotek Pharmaceuticals Corp., as detailed below:...
Jan 19, 2017 11:14 am ET
Pittsburgh Law Office of Alfred G. Yates Jr., PC Announces Investigation of Carbylan Therapeutics, Inc. (CBYL), currently known as KalVista Pharmaceuticals, Inc. (KALV)
PITTSBURGH, Jan. 19, 2017 /PRNewswire/ -- Law Office of Alfred G. Yates Jr., PC is investigating whether certain officers and directors of Carbylan Therapeutics, Inc. (NASDAQGM: CBYL) violated federal securities laws in connection with its initial public offering ("IPO").  Carbylan Therapeutics is a specialty pharmaceutical company that develops and commercializes novel and proprietary combination therapies....
Nov 22, 2016 07:30 am ET
KalVista Pharmaceuticals Announces Closing of Merger with Carbylan Therapeutics
—Combined company renamed KalVista Pharmaceuticals, Inc., listed on Nasdaq with ticker “KALV” —...